Clesrovimab has been shown to maintain RSV-protection in infants across 2 RSV seasons, while also having positive safety data.
Anushua Sinha, MD, MPH
Advertisement
Anushua Sinha, MD, MPH, is an infectious diseases physician at Merck.
Articles by Anushua Sinha, MD, MPH
Clinical trial data demonstrate that clesrovimab maintains a safety profile comparable to palivizumab while providing significant protection against RSV-related infections.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation
2
Colleen Cotton, MD, on the importance of early recognition in hidradenitis suppurativa
3
FDA approves ensitrelvir for post-exposure prevention of COVID-19 in adolescents and adults
4
FDA accepts mavacamten (Camzyos) application for adolescent obstructive hypertrophic cardiomyopathy
5